Work

Unorthodox Approach to the Development of a New Antituberculosis Therapy

Year: 2009

Type: article

Abstract: The development of TMC207 represents an important advance in the chemotherapy of tuberculosis. It is perhaps most amazing because of the defiantly unconventional nature of the effort. At virtually every step, from the original discovery of the diarylquinolines by screening for compounds that would kill Mycobacterium smegmatis, a saprophytic distant relative of M. tuberculosis, through the phase 2 study by Diacon et al. reported in this issue of the Journal (ClinicalTrials.gov number, NCT00449644),1 this effort flouted conventional wisdom about how to develop new drugs for tuberculosis.It is also a humbling case study that is worth some reflection. Those of . . .

Source: New England Journal of Medicine

DOI: 10.1056/nejme0903012

Author: Clifton E. Barry

Institution: National Institute of Allergy and Infectious Diseases

Language: English

Topic: Tuberculosis Research and Epidemiology

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institutes of Health